CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:32 2024-05-17 EDT			5-day change	1st Jan Change
3.36 ^SEK	+3.38%		-9.19%	+24.91%

03-13	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
02-21	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

BioStock: CombiGene's pain programme takes important steps forward

May 03, 2024 at 03:14 am

CombiGene is moving towards the toxicological studies in the COZY01 pain project, which is being conducted in collaboration with the Danish biotech company Zyneyro.
- We will continue to work methodically to complete the preclinical studies needed in order to be able to start the preclinical toxicology programme, says CombiGene's CEO Peter Ekolind.

Read the full interview with Peter Ekolind at biostock.se:

https://www.biostock.se/en/2024/05/combigenes-pain-programme-takes-important-steps-forward/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/combigene/r/biostock-combigene-s-pain-programme-takes-important-steps-forward,c3972773

Latest news about CombiGene AB

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	03-13	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-16	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	11-01	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	23-10-31	CI
CombiGene, Zyneyro to Start Clinical Studies of COZY01 Targeting Shingles	23-10-26	MT
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	23-10-26	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
CombiGene CEO to Depart in September	23-06-30	MT
CombiGene AB Announces Chief Executive Officer Changes	23-06-30	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	23-05-24	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	23-01-09	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Combigene AB Appoints Peter Ekolind as COO	22-09-27	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	22-02-21	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-17	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-17	CI
Combigene AB Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study	22-01-17	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI

Chart CombiGene AB

Duration

Period

More charts

Company Profile

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COMBIGENE AB	+24.91%	6.01M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs